Canaccord Genuity Maintains Buy on Exagen, Lowers Price Target to $9
Exagen Inc (XGN) (Q3 2026) Earnings Call Highlights: Record Q3 Revenue, 14th Straight ASP Gain, ...
Exagen (XGN) Q3 2026 Earnings Call Transcript
What Exagen (XGN) Said on Its Q3 Earnings Call
Exagen Inc. (XGN) Q3 2026 Earnings Call Transcript
Exagen Inc. (XGN) Reports Q3 Loss, Tops Revenue Estimates
Exagen Inc. Reports Third Quarter 2026 Financial Results
Exagen Files Prospectus For Offering $150M Mixed Shelf
Exagen Q3 2026 Earnings Call Transcript
Exagen Affirms FY2026 Sales Guidance of $72.000M-$75.000M vs $73.886M Est
Exagen Q3 EPS $(0.25) Misses $(0.18) Estimate, Sales $18.417M Beat $18.343M Estimate
Exagen Inc. to Participate in Upcoming Investor Conferences
Exagen to Announce Third Quarter Financial Results on November 10, 2026
Canaccord Genuity Maintains Buy on Exagen, Raises Price Target to $11
TD Cowen Maintains Buy on Exagen, Raises Price Target to $11
Full Transcript: Exagen Q2 2026 Earnings Call
Exagen (XGN) Q2 2026 Earnings Call Transcript
Exagen (XGN) Stock Gets Fair Value Boost As Analysts Weigh Growth And Execution
TD Cowen Maintains Buy on Exagen, Raises Price Target to $10
Exagen Inc. 2026 Q2 - Results - Earnings Call Presentation
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.